Compare ALNT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | ERAS |
|---|---|---|
| Founded | 1962 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | ALNT | ERAS |
|---|---|---|
| Price | $62.34 | $13.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $58.00 | $7.20 |
| AVG Volume (30 Days) | 169.4K | ★ 3.5M |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 67.09 | 36.23 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $554,478,000.00 | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $48.39 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $19.25 | $1.01 |
| 52 Week High | $70.00 | $16.14 |
| Indicator | ALNT | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 54.25 |
| Support Level | $51.88 | $1.46 |
| Resistance Level | $68.30 | N/A |
| Average True Range (ATR) | 3.85 | 1.02 |
| MACD | -0.42 | -0.20 |
| Stochastic Oscillator | 53.27 | 26.21 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty motion control components and systems. The firm primarily caters to the vehicle, medical, aerospace and defense, and electronics and industrial, pumps, and robotics sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.